Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.45 |
| ▸ | MEN1 | O00255 | 6/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3594499 | 0.77 | ACE (0.40) | MAPTLMNASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL9165337 | 0.74 | LMNA (0.54) | KMT2AMEN1MAPTLMNASMN1; SMN2 | |
| SCHEMBL13545419 | 0.70 | BRD4 (0.49) | KMT2AMAPTSMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL30908473 | 0.68 | IDH1 (0.48) | KMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL18177869 | 0.66 | KDM4E (0.66) | KMT2AMEN1MAPTLMNASMN1; SMN2 | |
| SCHEMBL30638850 | 0.66 | MEN1 (0.42) | KMT2AMEN1MAPTLMNASMN1; SMN2 | |
| SCHEMBL2191407 | 0.65 | KMT2A (0.56) | KMT2AMEN1MAPTLMNASMN1; SMN2 | |
| SCHEMBL28397102 | 0.65 | SMN1; SMN2 (0.57) | KMT2AMEN1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL22165853 | 0.65 | KMT2A (0.48) | KMT2AMEN1MAPTLMNASMN1; SMN2 | |
| SCHEMBL29541127 | 0.65 | KMT2A (0.48) | KMT2AMEN1MAPTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | KMT2A 906/4885MEN1 2424/4885MAPT 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.